Мақола

Current Status and Future Perspectives of CXCR4-based Radio-theranostics in Human Cancers

Baljinder SinghProfessor and Head, Department of Nuclear MedicineAnkit WattsNuclear Medicine Specialist, Department of Nuclear MedicineHarneet KaurVisiting Postdoc Researcher, Department of Nuclear MedicineSuraj KumarMuazzam NayeemAssociate Professor, Department of Nuclear MedicineKirti DhingraResearch Scholar, Department of Nuclear MedicinePankaj MalhotraProfessor and Head, Department of Clinical Haematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

Clinical Nuclear Medicinejournal2025en

ABI

Аннотация

Among the class of chemokine receptors, the G-protein coupled CXCR4 receptors are overexpressed in more than 30 human cancers. These receptors have been recognized as potential disease targets both for imaging and therapy. CXCR4 receptors are associated with tumor aggressiveness, increased risk of metastasis, and a higher probability of recurrence, which in turn leads to a poor prognosis. Ga-68 Pentixafor PET/CT has been reported to have a high affinity for CXCR4 receptors and offers efficient in vivo imaging suitable for the whole body CXCR4 disease mapping. Ga-68 Pentixafor, as a high throughput PET probe targeting CXCR4 receptors, has provided important diagnostic and prognostic information in human cancers. This PET radioligand provides favorable radiolabelling efficiency, stability, and safety profiling data. This review article discusses the Ga-68 Pentixafor PET/CT and Lu-177/Y-90 Pentixather as "theranostics pair" and their potential applications in hematological and solid cancers.

Ҳали таржима қилинмаган

Мавзулар

Chemokine receptors and signaling Radiopharmaceutical Chemistry and Applications Nanoplatforms for cancer theranostics

Идентификаторлар

DOI: 10.1097/rlu.0000000000005828

Иқтибослар ва манбалар

0 та иқтибос65 та фойдаланилган манба

Кўрсаткичлар — AkademScholar